TrialThe Lancet. Haematology2023

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.

Luciano J Costa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.